4-[(S)-2-Azetidin-1-yl-1-(3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxamide

ID: ALA4855657

Chembl Id: CHEMBL4855657

PubChem CID: 67633423

Max Phase: Preclinical

Molecular Formula: C20H20ClN5O

Molecular Weight: 381.87

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3cccc(Cl)c3)ncnc12

Standard InChI:  InChI=1S/C20H20ClN5O/c21-14-5-1-4-13(10-14)17(11-26-8-3-9-26)25-20-16-7-2-6-15(19(22)27)18(16)23-12-24-20/h1-2,4-7,10,12,17H,3,8-9,11H2,(H2,22,27)(H,23,24,25)/t17-/m1/s1

Standard InChI Key:  SIRZTYWYVGTPEV-QGZVFWFLSA-N

Associated Targets(Human)

AKT1 Tchem Serine/threonine-protein kinase AKT (9192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Aurora kinase B/Inner centromere protein (233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 381.87Molecular Weight (Monoisotopic): 381.1356AlogP: 3.24#Rotatable Bonds: 6
Polar Surface Area: 84.14Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.49CX LogP: 2.64CX LogD: 2.29
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.68Np Likeness Score: -1.40

References

1. DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, Chen X, Jones R, Richardson TE, Heasley BH, Haxell T, Moore J, Tian H, Georgi K, Rohdich F, Sutton A, Johnson T, Mochalkin I, Jackson J, Lin J, Crowley L, Machl A, Clark A, Wilker E, Sherer B, Goutopoulos A..  (2021)  Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.,  64  (19.0): [PMID:34596404] [10.1021/acs.jmedchem.1c01087]

Source